Enliven Therapeutics, Inc.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
1/10
|
285.84 | 48.77 | 486.1% | 96.39 | 196.55% |
| P/S |
|
0 | 33.76 | -100% |
|
|
| P/BV |
|
2.09 | 4.82 | -56.55% |
|
|
| P/FCF |
|
-13.15 | 60.98 | -121.57% |
|
|
| Ev/Ebitda |
|
-4.99 | -22.12 | -77.45% |
|
|
| Ev/S |
|
0 | 22.56 | -100% |
|
|
| Ev/FCF |
|
-6.76 | 68.75 | -109.83% |
|
|
| E/P |
|
-0.0886 | 0.0178 | -598.49% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
0 | 4.83 | -100% | 0 | 0% |
| ROE |
|
-29.11 | 9.61 | -403.04% |
|
|
| ROA |
|
-26.33 | 0.3359 | -7938.67% |
|
|
| ROIC |
|
0 | 7.63 | -100% |
|
|
| ROS |
|
0 | -25.17 | -100% |
|
|
| ROCE |
|
-33.97 | 15.33 | -321.56% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.004 | -3.67 | -99.89% | -0.0069 | -41.26% |
| Nеt Debt/Ebitda |
|
1.2 | -3.44 | -134.89% |
|
|
| Debt/Ratio |
|
0.0012 | 0.1972 | -99.37% |
|
|
| Debt/Equity |
|
0.0043 | 1.65 | -99.74% |
|
|
| Debt/Net Income |
|
-0.0047 | 10.31 | -100.05% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 0.5496 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 0.1053 | -100% |
|
|
| DSI |
|
0 | 0.2174 | -100% |
|
|
| Average dividend growth |
|
0 | 0.0654 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 0.4928 | -100% |
|
|
| Average percentage for payments |
|
0 | 43.56 | -100% |
|
|
| Difference from average difference in sector |
|
-0.5496 |
|
|
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % |
|---|---|---|---|---|
| Growth impulse Revenue 5 years |
0/10
|
0 | -56.89 | -100% |
| Growth impulse Ebitda 5 years |
|
250.14 | -64.81 | -485.96% |
| Growth impulse Net Income 5 years |
|
204.61 | -58.33 | -450.78% |
| Growth impulse FCF 5 years |
|
179.17 | -47 | -481.21% |
| Growth impulse EPS 5 years |
|
-18.8 | -32.41 | -41.99% |
IP Score
3.77/10
